Johnson & Johnson (NYSE:JNJ) Hit with $147M Verdict in Landmark Antitrust Case Over Reprocessed Medical Devices

A federal jury in Santa Ana has ordered Johnson & Johnson (NYSE:JNJ) to pay $147 million after its Biosense Webster unit was found guilty of violating antitrust laws. The court ruled J&J illegally withheld clinical support from hospitals using FDA-approved reprocessed catheters, directly undermining competition in the single-use device (SUD) market.

A medical technician holding the instruments in her hands

Plaintiff Innovative Health secured the major win, exposing Johnson & Johnson (NYSE:JNJ)’s alleged effort to block lower-cost, eco-friendly alternatives. The Association of Medical Device Reprocessors (AMDR) hailed the decision as a breakthrough for hospitals, patients, and sustainability efforts.

Johnson & Johnson (NYSE:JNJ) responded with disappointment, claiming its actions were pro-competitive and aimed at ensuring patient safety. The company is weighing an appeal.

The landmark verdict casts a spotlight on original equipment manufacturers’ (OEMs) market tactics and could trigger wider regulatory scrutiny across the medtech industry. JNJ is up by nearly 7% in 2025 so far.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.